Colonoscopy quality, as measured by adenoma detection rates, varies widely across providers and is inversely related to patients' post-colonoscopy cancer risk. This has unknown consequences for the benefits of faecal immunochemical testing (FIT) vs. primary colonoscopy screening for colorectal cancer. Using an established microsimulation model, we predicted the lifetime colorectal cancer incidence and mortality benefits of annual FIT vs. 10-yearly colonoscopy screening at differing ADR levels (quintiles; averages 15.3-38.7%), with colonoscopy performance assumptions estimated from community-based data on physician ADRs and patients' post-colonoscopy risk of cancer. For patients receiving FIT screening with follow-up colonoscopy by physicians from the highest ADR quintile, simulated lifetime cancer incidence and mortality were 28.8 and 5.4 per 1,000, respectively, vs. 20.6 and 4.4 for primary colonoscopy screening (risk ratios, RR 5 1.40; 95% probability interval (PI), 1.19-1.71 for incidence, and RR 5 1.22; 95%PI, 1.02-1.54 for mortality). With every 5% point ADR decrease, lifetime cancer incidence was predicted to increase on average 9.0% for FIT vs. 12.3% for colonoscopy, and mortality increased 9.9% vs. 13.3%. In ADR quintile 1, simulated mortality was lower for FIT than colonoscopy screening (10.1 vs. 11.8; RR 5 0.85; 95%PI, 0.83-0.90), while incidences were more similar. This suggests that relative cancer incidence and mortality reductions for FIT vs. colonoscopy screening may differ by ADR, with fewer predicted deaths with colonoscopy screening in higher ADR settings and fewer deaths with annual FIT screening in lower ADR settings.
Introduction
Colorectal cancer is a leading cause of cancer deaths that is preventable through screening. 1, 2 Colonoscopy is indispensable for colorectal cancer screening, as either a primary screening test or for diagnostic follow-up of positive tests results from other screening methods. Colonoscopy quality, as measured by adenoma detection rate (ADR), or the proportion of a physician's screening exams detecting adenomas, varies widely across providers. ADR has been shown to be inversely related to subsequent cancer incidence and mortality risks among patients undergoing screening colonoscopy. 3, 4 In a previous modelling study, we predicted that the observed ADR variation may translate to 50-60% differences in lifetime colorectal cancer outcomes for primary colonoscopy screening; however, few data exist regarding the potential influence of ADR variation on faecal-based CRC screening. 4 Annual faecal immunochemical testing (FIT) is increasingly used worldwide as either a primary colorectal cancer screening method or an adjunct to colonoscopy-based screening programmes to increase overall population screening rates. 5 FIT and colonoscopy screening strategies each have their advantages and disadvantages. Colonoscopy screening is more sensitive for cancers and adenomas and has a long screening interval. FIT may be more acceptable to patients because of the non-invasive nature, the lack of dietary restrictions, and lower risk of complications. 6 Although FIT screening requires diagnostic colonoscopy follow-up of positive results, the overall effectiveness of FIT-based screening may also be affected less by lower ADR levels than primary colonoscopy screening given FIT primarily detects more advanced lesions. [7] [8] [9] However, no data exist to compare the benefits of colonoscopy and FIT screening at different ADR levels. Modelling studies used to inform screening recommendations on comparative benefits of colonoscopy and FIT have assumed constant colonoscopy quality levels up to this point.
The purpose of our study is to use a modified microsimulation model informed by community-based data, 3 to compare the benefits of a programme of annual FIT vs. colonoscopy every 10 years at various ADR levels.
Material and Methods

Microsimulation screening analysis
Our study used the Microsimulation Screening AnalysisColon (MISCAN-Colon) model, developed by the Erasmus MC University Medical Center, Rotterdam, the Netherlands. The model, its main assumptions, and results for colonoscopy screening have been published. 4 The model has been used to inform the US Preventive Services Task Force recommendations for colorectal cancer screening, as well as national screening programmes. 10, 11 A detailed description of the model is included as a Supplementary Appendix. In brief, MISCAN-colon simulates an average-risk screening population similar to the United States population in terms of life expectancy and cancer risk to evaluate the effect of screening. Colorectal cancer is modelled as developing through the adenoma-carcinoma pathway. 12 Every simulated individual begins in a health state without colorectal cancer or precursor lesions. Throughout their simulated lifetime, individuals may develop one or more adenoma, which may develop progressively from small size (5 mm in diameter), to medium size (6-9 mm) to large size (10 mm), and to stages I-IV cancer. Cancer may progress from stages I through IV without symptoms, or may be clinically diagnosed in any of the states. Patients may die from cancer or may die from other causes first. In the model, screening has the potential to alter patient's life histories by detecting cancer in an earlier, more treatable stage, or by detecting and removing precursor adenomas.
The effectiveness of screening follows from the natural history assumptions and a screening test's assumed ability to detect adenomatous lesions. Effects of screening have been shown previously to be concordant with results from randomised controlled trials of faecal-occult blood testing. 13 Results have also been validated against the estimated mortality reduction from the UK flexible sigmoidoscopy screening trial ( Supplementary Fig. S3 ). 14, 15 Although no experimental data were available to directly validate the modelled effectiveness of FIT and colonoscopy screening, effect sizes were concordant with observational data ( Supplementary Figs. S4 and S5). 16, 17 Predicted mortality risks after polypectomy were validated against long-term National Polyp Study observations ( Supplementary Fig. S6 ).
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Test performance assumptions
In our study, assumed variation in colonoscopy performance was based on previously published data from Kaiser Permanente Northern California, an integrated healthcare delivery system in the United States with a well-defined denominator population. 3 Corresponding estimates of per-lesion sensitivity of colonoscopy varied from quintile 1 to 5: 14.7-98% for adenomas of 0-5 mm in diameter, 39.6-98% for adenomas of 6-9 mm and 88.0-98% for adenomas of 10 mm (Table 1; see  Supplementary Appendix for the methodology) . 4 The assumed rate of colonoscopy completeness was fixed at 98% for all ADR quintiles. Complication rates for colonoscopy with polypectomy were assumed to increase exponentially with age, from 0.4 per 1,000 at age 50 years to 8.5 per 1,000 at age 100 years. 19 The modelled effectiveness of FIT-based screening (OC Sensor test with a positivity cut-off of 20 mg/g cut-off) is based on both the sensitivity and specificity of FIT and the sensitivity and completeness of the colonoscopy exam used for follow-up of positive FIT results. Colonoscopy performance assumptions were varied according to ADR level as described above. Assumed per-lesion sensitivity of FIT was derived from recently published observational data, and was 4.9% for adenomas of 6-9 mm, 16.2% for adenomas 10 mm and 64-89% for cancer (Table 1) . 7 
Analysis
For our study, MISCAN-Colon was used to generate an average-risk screening population of 10 million men and women born on January 1, 1965. Patients received annual FIT between the ages 50 and 75 years. 20 Patients with a posi- adenomas detected in screening received colonoscopy surveillance according to the most current guidelines. 21 We compared colorectal cancer outcomes for FIT according to level of adenoma detection. For reference, we also simulated outcomes with colonoscopy screening and without any screening. Primary study outcomes were simulated lifetime colorectal cancer incidence and mortality rates according to ADR quintile (undiscounted). We also predicted the continuous change in outcomes per 5% point increase in ADR using linear regression. Furthermore, we also simulated the burden of screening according to ADR quintile, as measured by the required number of follow-up and surveillance colonoscopies, and the associated complications. Multivariate probabilistic sensitivity analysis was used to derive 95% probability intervals (95% PI) for all model outcomes. In 1,000 simulation runs of 10 million persons we varied 13 key parameters along uniform, beta or lognormal distributions. 4 FIT performance assumptions were also varied ( Table 1) . We conducted additional sensitivity analyses repeating our estimation of the continuous change in outcomes for every 5% point lower ADR, assuming 5-15% point lower or higher FIT sensitivity, 1.25% point lower or higher FIT specificity, assuming dependency in FIT performance in individuals across study rounds (50% correlated false-positive or falsenegative results), varying the colonoscopy completion rate 75-98% in association with observed ADR variation, and also varying the extent to which ADR variation was attributed by the model to colonoscopy sensitivity for diminutive lesions.
In the one extreme, all ADR variation was attributed to variation in small adenoma miss rates; in the other extreme, physicians were assumed to miss all sizes of lesions with equal probability. In addition, we evaluated the impact of ADR for biennial FIT screening, which is recommended and used in many settings.
Role of the funding source
This work was funded by the United States National Cancer Institute. The funder played no role in the design of the study, the analysis and interpretation of the data, and the writing and submission of this report.
Results
Among unscreened patients, the simulated lifetime risk of colorectal cancer was 66.8 (95%PI, 50.7-85.1) per 1,000, and the simulated risk of colorectal cancer mortality was 27.8 (95%PI, 20.8-36.5) per 1,000 ( Fig. 1 , Table 2 ).
Screening effectiveness
Among patients screened with annual FIT (with colonoscopy follow-up for positive results), the average simulated colorectal cancer incidence and mortality risks were 37.9 (95%PI, 27.9-50.7) and 7.4 (95%PI, 5.3-10.2) per 1,000, respectively (Table 2) . Among patients screened with colonoscopy, the average simulated colorectal cancer incidence and mortality risks across all ADR quintiles were 33.4 (95%PI, 24.8-42.8) and 7.7 (95%PI, 5.6-10.2) per 1,000, respectively. The adenoma sensitivity estimates for FIT (OC Sensor, cut-off >20 mg/g) were obtained by calibrating our model outcomes to the estimated perperson sensitivities from Imperiale et al. 7 The per-person sensitivity of FIT for adenomas, advanced adenomas and cancer was 7.6, 23.8 and 73.8, respectively. We assumed that faecal occult blood testing is more sensitive in cancers towards the end of the occult invasive period (close, timewise, to becoming symptomatic): for preclinical cancers which will become symptomatic within the same stage, assumed test sensitivity was higher. This assumption showed good concordance with guaiac faecal occult blood test trial results. 13 Colonoscopy sensitivity estimates were derived elsewhere. 4 3 The probability of a false-positive result was random in the base-case analysis, and independent of person or lesion. We assumed perfect specificity for colonoscopy including pathological examination of detected lesions. 4 This is the proportion of colonoscopies visualising the maximum point of reach of the endoscope, i.e. the caecum. 5 Standard deviation for the probabilistic sensitivity analysis is shown in brackets. A Beta distribution was assumed to reflect uncertainty. A difference of 1/25% point in assumed test sensitivity or of 2/12% in specificity corresponds roughly to a cutoff difference of 1 20/210 mg blood per g faeces. 37 
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The outcomes of FIT screening and primary colonoscopy screening varied according to level of adenoma detection. Among patients receiving annual FIT screening with potential follow-up colonoscopy from providers in the highest ADR quintile, incidence was 28.8 (95%PI, 20.9-40.8) and mortality 5.4 (95%PI, 3.7-7.8) (Fig. 1) . In contrast, for patients receiving colonoscopy screening from the highest ADR quintile providers, the simulated lifetime cancer incidence and mortality were 20.6 (95%PI, 15.4-27.1) and 4.4 (95%PI, 3.2-5.9) per 1,000, respectively (risk ratios for FIT vs. colonoscopy, RR 5 1.40; 95%PI, 1.19-1.71, and RR 5 1.22; 95%PI, 1.02-1.54) (Fig. 2) . For every 5% point decrease in ADR, incidence was predicted to increase on average 9.0% (95%PI, 6.7-10.5) for FIT screening and 12.3% (95%PI, 11.1-12.9) for colonoscopy screening ( Fig. 3 ). Simulated mortality in quintile 1 was lower with primary FIT than with primary colonoscopy, at 10.1 per 1,000 (95%PI, 7.3-13.6) vs. 11.8 per 1,000 (95%PI, 8.6-15.8), respectively (RR 5 0.85; 95%PI, 0.83-0.90) (Figs. 1 and 2) .
The ratio of simulated mortality risks in each quintile compared to the average simulated risk across quintiles, varied 0.73-1.37 for FIT screening (from quintile 5 to quintile 1), and 0.57-1.53 for colonoscopy screening ( Table 2) . Simulated variation in incidence ratios across quintiles was similar.
Screening burden
Among patients receiving FIT screening, the number of required follow-up and surveillance colonoscopies varied 
Sensitivity analysis
Outcomes were sensitive to the assumed test characteristics for FIT and colonoscopy (Table 3 ). The relative increase in cancer mortality per 5% point lower ADR was smaller for FIT screening when assuming lower FIT sensitivity (8.7%), higher assumed FIT specificity (7.6%), or with dependency of false test results (7.9%), and larger when assuming higher FIT sensitivity (10.8%) or lower specificity (11.3%). When ADR variation was attributed predominantly to small adenomas, the mortality change was lower for both colonoscopy (11.3%) and FIT (7.7%), while with variation in colonoscopy completion or more variation in detection of larger adenomas, mortality changes were larger than the base-Case (13.5-14.1% for colonoscopy and 11.1-12.6% for FIT). In all scenarios, ADR variation influenced outcomes more for colonoscopy screening than FIT screening.
In a simulated scenario of biennial FIT screening, which was less effective on average than annual FIT screening, colorectal cancer incidence and mortality were relatively more stable to ADR variations, with predicted relative increases in incidence and mortality of 6.1% per 5% point lower ADR. Whiskers represent 95% probability intervals from multivariate probabilistic sensitivity analysis. See Figure 3 for a plot of outcomes against actual, average ADR levels per quintile. Risk ratios compared to the average risk across quintiles. 3 Colonoscopy without polypectomy was not associated with a higher risk of complications. The risk of complications for polypectomy increased exponentially with age. Complications include serious gastrointestinal events such perforation and gastrointestinal bleeding requiring blood transfusions; other gastrointestinal events such as paralytic ileus, nausea, vomiting and dehydration, and abdominal pain and cardiovascular events such as myocardial infarction or angina, arrhythmias, congestive heart failure, cardiac or respiratory arrest, or syncope, hypotension, or shock. The fatal perforation rate was derived from estimates of the incidence of perforation and case fatality for perforation.
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Discussion
Using advanced modelling techniques, we showed that there is an inverse relationship between physicians' observed ADR and colorectal cancer screening outcomes that may be stronger when primary screening is performed with colonoscopy than with FIT. Although FIT-based and colonoscopy-based screening strategies had similar average predicted mortality reductions in line with previous estimates, 10 with varying ADRs, the outcomes may differ. For providers from the highest ADR quintile, the model suggested that primary colonoscopy screening would result in fewer colorectal cancer cases and deaths than FIT screening, while conversely, FIT screening outperformed colonoscopy in terms of mortality reductions when physician ADRs levels were <20% (male and female patients combined).
The simulated outcome differences between FIT and colonoscopy screening can be explained by the different test characteristics. While colonoscopy, with relatively long screening intervals, provides long-term protection through removal of most existing lesions at the time of screening, 22 the more frequent FIT screening with follow-up colonoscopy of positive results may primarily detect large adenomas and early-stage cancers before they progress to more advanced-stages. 7 The model assumed that physicians with lower detection rates have a higher proclivity for missing small rather than large adenomas. 4, 23 Therefore, FIT outcomes were relatively more stable to varying ADRs than primary screening with colonoscopy (9.4% vs. 13.3% predicted increase in disease-related mortality per 5% point ADR decrease). In an alternative model with more assumed variation in sensitivity of colonoscopy for large adenomas (Table 2) , outcomes still remained more stable for FIT than colonoscopy, but the differences were smaller (12.6% vs. 14.1% increase in mortality per 5% point ADR decrease).
Another consequence of the different test characteristics of colonoscopy and FIT is that, although annual FIT was predicted to be more effective for preventing colorectal cancer deaths than low-quality screening colonoscopy, primary colonoscopy screening resulted in lower simulated colorectal cancer incidences across all ADR quintiles. This is a potential advantage for colonoscopy screening, which has induced some expert panels to favour colonoscopy over other less invasive modalities for colorectal cancer screening. 24 In contrast, given the different risk and benefit profiles of different screening strategies, the most recent recommendation by the US Preventive Services Task Force puts more emphasis on patient preferences and shared decision-making. 2 European experts prefer faecal testing for screening given the strength of evidence from randomised trials to support these strategies, and the lower burden of testing.
To our knowledge, our study is the first to have looked at the influence of ADRs on screening outcomes for a stoolbased screening setting. Previous empirical studies have found inverse associations between physician ADR levels and post-colonoscopy cancer risk. [25] [26] [27] In the largest study to this date, Corley and colleagues found associations between ADR and interval cancer risk that were similar for screening, diagnostic and surveillance exams. 3 A prior modelling study predicted that commonly observed ADR variation may translate to 50-60% differences in lifetime colorectal cancer outcomes for primary colonoscopy screening. 4 Our study suggests that variations in ADR may have less influence on the outcomes of FIT, with maximum predicted outcome differences of approximately 45%.
Our study may overestimate the outcome differences for faecal testing. First, many settings use biennial rather than annual FIT screening. Our sensitivity analyses found that outcomes of screening were more stable to ADR variation with less frequent (biennial) FIT screening than annual screening, which may be explained by a larger proportion of Figure 2 . Simulated relative risks of colorectal cancer incidence (a) and mortality (b) for FIT vs. colonoscopy screening.
a Abbreviation: ADRqi, adenoma detection rate quintile i (i 5 1,. . .,5). a Whiskers represent 95% probability intervals from multivariate probabilistic sensitivity analysis. The variable width of probability intervals from the probabilistic sensitivity analysis was due to interaction of colonoscopy and FIT performance: in the model, lower ADRs decreased the outcome effect of FIT's variable false-positive rates and the associated colonoscopy receipt, and higher ADRs increased the effect. [Color figure can be viewed at wileyonlinelibrary.com] adenomas presenting as advanced adenomas. Furthermore, while multiple studies have shown that there is substantial variation in ADRs from screening exams, 3, 28, 29 there are less data available on variation in adenoma detection during colonoscopies after positive faecal colorectal cancer screening test results. Physicians may examine a patient more carefully with evidence of gastrointestinal blood loss, which may improve adenoma detection, even for small adenomas that are unlikely to have caused the positive test result. Although ADRs in diagnostic examinations are not directly comparable to those in screening exams, wide variation in detection rates across physicians within population-based FIT screening settings suggest that miss rates may also vary substantially. 8, 9 High observed risks of cancer after positive FITs followed by negative colonoscopies (for adenomas) could also be indicative of suboptimal quality.
A limitation of our study is the lack of direct experimental data to inform the model on efficacy of FIT and colonoscopy screening. 6 We modelled the average efficacy of FIT using an established approach used before in a decision analysis to inform the US Preventive Services Task Force. 10 This approach combines evidence from guaiac faecal occult blood testing trial data with observational data on FIT's diagnostic performance. 7, 30 Colonoscopy efficacy predictions were derived similarly using flexible sigmoidoscopy trial results. The predicted effects in our study for colonoscopy and FIT were substantively larger than the effects found for guaiacbased faecal testing and sigmoidoscopy, which may be partly due to better performance characteristics, and to assumed high patient adherence in our study. The simulated mortality effects of FIT are comparable to results from a recent major population-based study (for exposed vs. unexposed people), 16 and colonoscopy effects are within the outcome range of observational studies, 17 supporting the use of this approach for our study.
Our study focused on the influence of observed ADR variation on screening effectiveness. There are other important outcomes, such as cost and cost-effectiveness, and modifiable outcome determinants for colonoscopy and FIT, including ambient FIT temperature, 31 adherence with and time from a positive FIT to diagnostic colonoscopy follow-up, 32 and particularly, patient adherence with annual or biennial FIT. 33 Our assumption of 100% adherence with both colonoscopy and FIT screening does not represent actual practice, but provides maximum achievable effects for both screening modalities, in line with previous decision analyses. In actual FIT, faecal immunochemical test; ADR, adenoma detection rate. 1 Mean simulated outcome differences per 5% decrease in ADR were derived by linear regression and presented relative to the model outcomes for ADR quintile 1 (5 3 b ols /outcome q1 ). The actual ADR-outcome relationship was slightly convex (rather than perfectly linear), particularly for FIT screening outcomes: the outcome impact of ADRs changes was somewhat larger at lower baseline ADR levels than at higher levels (see Fig. 3 ). 2 We assumed 5% point lower/higher sensitivity of FIT for adenomas, and 10-15% point lower/higher values for cancer. 3 We assumed 2.5% point lower/higher specificity of FIT. 4 It was assumed that patients with a false-negative result were likelier than average to test negative again in subsequent screening rounds, Similarly, false-positive results were assumed to occur predominantly in specific patients with an inclination for faecal blood loss from causes other than adenoma. Positivity decreases as soon as these predisposed patients become ineligible for screening (i.e., after follow-up colonoscopy receipt). 5 With more emphasis on small adenomas, all variation in ADRs was attributed to sensitivity of colonoscopy for adenomas smaller than 5 mm, which varied from 5.4%, lowest, to 98%, highest quintile. With less emphasis, all ADR variation was attributed equally to sensitivity for small, medium and large adenomas, which varied from 26.0% to 98%. With variation in caecal intubation rates, ADR variation was attributed to both colonoscopy sensitivity and reach, the latter varying from 75% to 98% from lower to higher ADR quintiles. 6 Biennial FIT screening resulted in higher CRC incidence and mortality risks than annual FIT screening of, on average, 45.1 and 9.9 per 1,000 patients, respectively.
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practice, adherence may differ for colonoscopy and FIT. With more data on patient adherence over time, future modelling studies could inform priorities of quality-related interventions by assessing and ranking the relative contribution of quality in comparison to adherence. A strength of our study is that we based our estimates for variable colonoscopy performance characteristics on empirical data regarding interval cancer incidence rates after colonoscopy screening according to physician ADR. 3 Our assumptions have been shown to match well with the observed decreasing incidence pattern from lower to higher ADRs. 3, 4 Alternative models with relatively more or less emphasis on variation in detection of diminutive lesions and variable colonoscopy completion rates, as evaluated in sensitivity analyses, matched the data less well, which suggests that our base-case assumptions are reasonable. However, we cannot rule out other possible explanations for the observed incidence pattern, such as an association of ADR with adequate polyp management or serrated polyp detection rates.
Our study has three main implications. First, the study results are consistent with the results of the most recent decision analysis for the US Preventive Services Task Force in finding similar overall estimated mortality reductions for annual FIT screening and colonoscopy screening strategies. This confirms that if no information is available on ADRs, both strategies are potentially equivalent in terms of the predicted mortality reduction. The average predicted benefits across ADR quintiles in our study were somewhat more conservative (20 deaths averted per 1,000 patients) than the estimated benefits in the USPSTF analysis (23 and 24 death averted, respectively). The difference is mainly due to the alternative diagnostic performance assumptions for colonoscopy as used in our study.
Second, physician ADR is an important indicator for colorectal cancer screening performance, irrespective of whether the primary screening modality is colonoscopy or FIT. This underscores the importance of ongoing efforts to measure and benchmark physicians' ADR scores, 34 as formalised in some quality assurance programmes. 35 Research suggests that endoscopist training programmes may be effective at increasing ADR levels. 36 If large population-based studies confirm that such programmes have also a favourable impact on cancer-related outcomes, other screening programmes should consider offering similar trainings to improve screening effectiveness. Finally, our results suggest that ADR may be useful not only as a quality indicator for screening, but may also affect comparative screening programme performance and outcomes. We found that the benefits of FIT relative to colonoscopy screening may differ depending on the quality of colonoscopy achieved in a particular programme. This observation suggests that available colonoscopy quality may be one of the relevant factors that policy makers may consider in selecting the most appropriate screening method for their particular setting. Research is needed to further investigate from what number of exams ADR can be reliably estimated and used as a predictor of both screening outcomes in general, and comparative performance of alternative screening methods in particular.
To conclude, the relative cancer incidence and mortality reductions for annual FIT vs. colonoscopy screening may differ based on colonoscopy quality, as measured by ADR. Although the predicted mortality benefits are similar for FIT and colonoscopy with average ADR levels, colonoscopy screening may result in fewer cancer deaths in settings with higher ADR levels, while annual FIT screening may result in fewer deaths in lower ADR settings.
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